Voxelotor in sickle cell disease: There’s HOPE in the HOPE trial
Following receipt of an email from The NEJM, about the notable articles of 2019, one paper stood out for me - this involved the clinical phase 3 trial of voxelotor…
source: indiamart
Hydroxyurea in sickle cell disease: Recommendations of use.
We’ve enjoyed three articles about hydroxyurea so far. Let’s summarize the recommendations for the administration of hydroxyurea alias Hydroxycarbamide. These are; Educate all patients with SCA and their family members…
Hydroxyurea in sickle cell disease: Administration and Adverse Effects: Part 3
No drug is safe to administer to any patient, not even vitamin supplements. And because hydroxyurea is an anticancer per se, documentation that includes, but not limited to informed consent…
Hydroxyurea in sickle cell disease: These features make it a perfect therapeutic agent: Part 2.
If you’ve read the previous article about the vital facts about hydroxyurea in sickle cell disease, you now have an idea about the drug. There are features that any therapeutic…
source: indiamart
Hydroxyurea in sickle cell disease: What You Need To Know: Part 1
It is not very common that a drug like hydroxyurea is so exceptionally incredible, yet it has not gained as much traction and attention as it should have. It may…
Chronic eye complications in sickle cell disease: Everyone has a role to play.
We said in the previous articles that the management of sickle cell disease requires a multidisciplinary approach with the primary clinician at the centre of it. Chronic eye complications strictly…